Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

The dynamics of chronic gout treatment: medication gaps and return to therapy.

Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, Ockene IS.

Am J Med. 2010 Jan;123(1):54-9. doi: 10.1016/j.amjmed.2009.05.026.

2.

Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?

Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr.

J Rheumatol. 2001 Mar;28(3):577-80.

PMID:
11296962
3.

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ.

BMC Musculoskelet Disord. 2012 Sep 16;13:174. doi: 10.1186/1471-2474-13-174.

4.

Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.

Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH.

Am J Med. 2007 Mar;120(3):251-6.

PMID:
17349448
5.

Stopping progression to tophaceous gout. When and how to use urate-lowering therapy.

McDonald E, Marino C.

Postgrad Med. 1998 Dec;104(6):117-20, 123-4, 127.

PMID:
9861261
6.

Adherence with urate-lowering therapies for the treatment of gout.

Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS.

Arthritis Res Ther. 2009;11(2):R46. doi: 10.1186/ar2659. Epub 2009 Mar 27.

7.

A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.

Perez-Ruiz F, Herrero-Beites AM, Carmona L.

Arthritis Rheum. 2011 Dec;63(12):4002-6. doi: 10.1002/art.30649.

8.

Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC.

Rheumatol Int. 2015 Nov;35(11):1799-807. doi: 10.1007/s00296-015-3284-3. Epub 2015 May 20.

9.

Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Hill EM, Sky K, Sit M, Collamer A, Higgs J.

J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.

PMID:
25807090
10.

Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.

Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI.

Nephron. 2000 Nov;86(3):287-91.

PMID:
11096285
11.

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.

PMID:
19485724
12.

[Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].

Kolyvanos Naumann U, Suter PM, Käser L, Vetter W.

Praxis (Bern 1994). 2005 Apr 6;94(14):543-8; quiz 549. Review. German. No abstract available.

PMID:
15849976
13.

Gout: an update.

Eggebeen AT.

Am Fam Physician. 2007 Sep 15;76(6):801-8. Review.

14.

Sex differences in gout epidemiology: evaluation and treatment.

Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG.

Ann Rheum Dis. 2006 Oct;65(10):1368-72. Epub 2006 Apr 27.

15.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
16.

Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.

Khanna PP, Perez-Ruiz F, Maranian P, Khanna D.

Rheumatology (Oxford). 2011 Apr;50(4):740-5. doi: 10.1093/rheumatology/keq346. Epub 2010 Dec 8.

17.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

18.

[Hyperuricemia and gout--treatment].

Gröbner W, Walter-Sack I.

Dtsch Med Wochenschr. 2002 Feb 1;127(5):210-3. German. No abstract available.

PMID:
11821994
19.

[Clinical features of gout in a cohort of Italian patients].

Zampogna G, Andracco R, Parodi M, Cimmino MA.

Reumatismo. 2009 Jan-Mar;61(1):41-7. Italian.

20.

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Singh JA, Akhras KS, Shiozawa A.

Arthritis Res Ther. 2015 May 12;17:120. doi: 10.1186/s13075-015-0624-3. Erratum in: Arthritis Res Ther. 2015;17:236.

Items per page

Supplemental Content

Write to the Help Desk